You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
摩通:上調百濟神州(6160.HK)目標價至129港元 評級“增持”
格隆匯 11-04 11:15
摩根大通發表報告指,百濟神州(6160.HK) 公佈獲美國藥廠安進(Amgen)斥資27億美元入股20.5%權益,集團可得到安進三種晚期藥物在中國的商業化經營,並獲得對方20種早期創新腫瘤藥物的全球使用權。該行認為,百濟神州與安進的戰略合作具有轉化潛力,將集團股份目標價由97港元上調至129港元,評級“ 增持 ”。
摩通認為,本次交易顯示了集團領先的商業化及臨牀能力,以及中國的腫瘤學市場具有吸引力。除了從安進獲得多種藥物外,該行相信對方以溢價26%斥資27億美元入股,亦可加強百濟神州的資產負債表。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account